Monitoring fluoropyrimidine metabolism in solid tumors with in vivo 19F magnetic resonance spectroscopy

被引:21
|
作者
van Laarhoven, HWM [1 ]
Punt, CJA
Kamm, YJL
Heerschap, A
机构
[1] Univ Nijmegen, Med Ctr, Dept Med Oncol 550, NL-9101 HB Nijmegen, Netherlands
[2] Univ Nijmegen, Med Ctr, Dept Radiol, NL-6500 HB Nijmegen, Netherlands
关键词
5-fluorouracil; capecitabine; tegafur; NMR; spectroscopy; F-19; review;
D O I
10.1016/j.critrevonc.2005.03.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
(19)Fluorine magnetic resonance spectroscopy (F-19 MRS) offers unique possibilities for monitoring the pharmacokinetics of fluoropyrimidines in vivo in tumors and normal tissue in a non-invasive way, both in animals and in patients. This method may therefore be useful for predicting response to fluoropyrimidine-based therapy with or without the effects of modulating agents, and this may be of value for the individualization of anticancer therapy and the strategic development of new anticancer drugs. F-19 MRS has been very valuable in elucidating the basic aspects of fluoropyrimidine metabolism, especially in animal studies. Studies in humans have indicated its clinical potential, but widespread application has been hampered by the relatively low detection sensitivity of the method. The recent introduction of clinical MR scanners with magnetic fields above 1.5 T may stimulate increased clinical use of F-19 MRS. (c) 2005 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:321 / 343
页数:23
相关论文
共 50 条
  • [1] Fungal metabolism of toluene:: Monitoring of fluorinated analogs by 19F nuclear magnetic resonance spectroscopy
    Prenafeta-Boldú, FX
    Luykx, DMAM
    Vervoort, J
    de Bont, JAM
    APPLIED AND ENVIRONMENTAL MICROBIOLOGY, 2001, 67 (03) : 1030 - 1034
  • [2] Monitoring of inflammatory processes by in vivo 19F magnetic resonance imaging
    Floegel, Ulrich
    Ding, Zhaoping
    Hardung, Hendrik
    Jander, Sebastion
    Reichwein, Gaby
    Jacoby, Christoph
    Schubert, Rolf
    Schrader, Juergen
    CIRCULATION, 2007, 116 (16) : 410 - 411
  • [3] In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors
    Procissi, Daniel
    Claus, Filip
    Burgman, Paul
    Koziorowski, Jacek
    Chapman, J. Donald
    Thakur, Sunitha B.
    Matei, Cornelia
    Ling, C. Clifton
    Koutcher, Jason A.
    CLINICAL CANCER RESEARCH, 2007, 13 (12) : 3738 - 3747
  • [4] 19F Magnetic Resonance Imaging and Spectroscopy in Neuroscience
    Modo, Michel
    NEUROSCIENCE, 2021, 474 : 37 - 50
  • [5] In vivo effect of 5-ethynyluracil on 5-fluorouracil metabolism determined by 19F nuclear magnetic resonance spectroscopy
    Adams, ER
    Leffert, JJ
    Craig, DJ
    Spector, T
    Pizzorno, G
    CANCER RESEARCH, 1999, 59 (01) : 122 - 127
  • [6] In Vivo F-19 Magnetic Resonance Spectroscopy
    Heerschap, Arend
    EMAGRES, 2016, 5 (02): : 1283 - 1289
  • [7] Responsive fluorinated lanthanide probes for 19F magnetic resonance spectroscopy
    Senanayake, P. Kanthi
    Kenwright, Alan M.
    Parker, David
    van der Hoorn, Susanna K.
    CHEMICAL COMMUNICATIONS, 2007, (28) : 2923 - 2925
  • [8] Fluorine Labeling of Nanoparticles and In Vivo 19F Magnetic Resonance Imaging
    Manuel Arango, Juan
    Padro, Daniel
    Blanco, Jorge
    Lopez-Fernandez, Sonia
    Castellnou, Pilar
    Villa-Valverde, Palmira
    Ruiz-Cabello, Jesus
    Martin, Abraham
    Carril, Monica
    ACS APPLIED MATERIALS & INTERFACES, 2021, 13 (11) : 12941 - 12949
  • [9] Calcium Fluoride Nanocrystals: Tracers for In Vivo 19F Magnetic Resonance Imaging
    Ashur, Idan
    Allouche-Arnon, Hyla
    Bar-Shir, Amnon
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2018, 57 (25) : 7478 - 7482
  • [10] Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivo 19F magnetic resonance spectroscopy
    Payne, GS
    Collins, DJ
    Loynds, P
    Mould, G
    Murphy, PS
    Dzik-Jurasz, ASK
    Kessar, P
    Haque, N
    Yamaguchi, M
    Atarashi, S
    Leach, MO
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (02) : 244 - 248